

Scan the QI code to download

Fopical Minoxid or hair loss in





Patient information

Topical Minoxidil for hair loss in women

What is topical Minoxidil and how does it work?

Minoxidil tablets were originally used to treat high blood pressure. It was found that a side effect of this treatment was increased hair growth. This led to the development of a topical solution of minoxidil which can be used directly on the scalp as a treatment for certain types of hair loss. How minoxidil works to improve hair growth isn't fully understood but it is thought that it is through increased blood supply to the hair follicle. It makes hair grow for longer and encourages hairs to grow more quickly.

How to use topical minoxidil

Minoxidil can be bought without a prescription. There are several different preparations including liquids, sprays and foams. It is available in different strengths such as 2% and 5%. There are also different brand names. Regain is probably the most well-known brand but any brand that contains the correct strength is acceptable. For women, generally 5% once or twice daily is recommended.

Minoxidil should be applied onto the scalp. The hair should be sectioned into a parting and the product applied, then another section created. This should be continued until all areas of scalp that require treatment are covered. Once applied you can rub it in.

Wash your hands thoroughly after use. Avoid getting your hair wet for at least four hours after application. You do not have to wash your hair daily when using Minoxidil.

Who can use topical minoxidil?

Topical Minoxidil is designed for female pattern hair loss but can have benefits for other hair loss conditions too such as telogen effluvium, alopecia areata, frontal fibrosing alopecia, etc. If it has been recommended for you it is because it may help some aspects of your condition. Certain hair conditions will not respond to topical Minoxidil so the use of this product should ideally be guided by a specialist.

You should not use this if you are pregnant or trying to conceive.

It is not licensed for patients over the age of 65, however, it is commonly used in patients over that age. It may not be appropriate if you have certain heart conditions such as ischaemic heart disease. You will be advised if it is not suitable for you.

You should also not use topical minoxidil if you are allergic to it or any of the ingredients. The solution contains propylene glycol but the foam preparation does not.

What are the potential complications?

In the first few weeks of starting treatment, topical minoxidil may cause increased hair shedding or fall which then settles. Some preparations can cause scalp irritation. It may cause excess facial hair growth which is reversible on stopping treatment. It can also cause headaches, dizziness/light headiness and heart palpitations. All other side effects, such as ankle swelling and tinnitus, are rare.

Its benefits are usually not noticeable straight away and it often takes over a year-and-a-half of use in women before improvements can be seen, but it may be seen sooner in some cases.

Topical minoxidil only works whilst the product is still being used. Ongoing benefits require continued use. Once treatment is stopped the benefits disappear within a few weeks. For most conditions its use is therefore often required in the long term.

How to contact us

Dermatology Department Watford General Hospital

Vicarage Road Watford Hertfordshire, WD18 0HB

Hospital switchboard: 01923 244366

PALS

If you need this leaflet in another language, large print, Braille or audio version, please call 01923 217198 or email westherts.pals@nhs.net.











Language

Large Print

Braille

Audio

Concerns, complaints or suggestions

If you are unhappy with your experience or would like to give feedback, please contact our Patient Advice and Liaison Service (PALS). PALS is available to patients, relatives, carers and friends to raise concerns.

For more information, please scan the QR code or visit our website.

Author	Dr Caroline Champagne
Department	Dermatology
Ratified / review date	August 2023 / August 2026
ID number	23/2121/V1